Strontium-89 chloride delivery for painful bone metastases in patients with a history of prior irradiation

Autor: Anneyuko I. Saito, Tatsuya Inoue, Makiko Kinoshita, Takahiro Kosaka, Taira Mitsuhashi
Rok vydání: 2022
Předmět:
Zdroj: Irish Journal of Medical Science (1971 -). 192:569-574
ISSN: 1863-4362
0021-1265
Popis: Re-irradiation of a previously irradiated site must be done with careful consideration to minimize dose to organs at risk.To evaluate pain response and safety of Sr-89 administration for painful bone metastases after prior irradiation.We retrospectively reviewed patients with Sr-89 injection for painful bone metastasis in a previously irradiated site. All patients were seen in follow-up at 1, 2, 3, and 4 months after injection and every 6 months thereafter. Pain control, toxicity, and pain progression-free survival were analyzed. Correlation of pain relapse with the following characteristics was analyzed: gender, age, primary tumor, tumor pathology, baseline performance status, and baseline verbal rating scale.Among 25 patients analyzed (10 male, 15 female), median age was 68 (range, 50-81) years. Primary tumor sites included lung (n = 11), breast (n = 3), uterine cervix (n = 3), prostate (n = 3), and others (n = 5). Median follow-up was 25 (range, 1-76) months. Pain relief was observed in 24 patients (96.0%). One- and 2-year pain progression-free survival rates in these patients were 54.5% and 48.4%, respectively. Median time to pain progression was 5 (range, 2-16) months. Statistically significantly lower pain progression-free survival was observed in patients with osteolytic bone metastases (p 0.01). No grade 3 or worse adverse events were observed.Sr-89 injection showed pain relief in most of our patients with painful bone metastases in a previously irradiated site and caused no grade 3 or worse adverse events. Sr-89 is an option for patients with a painful bone metastasis in a previously irradiated site.
Databáze: OpenAIRE
Externí odkaz: